?????????????????????????????????讓生命更精彩，讓生活更美好
陜西慧康生物科技有限責任公司，成立于2001年，專注于生物科技前沿領域“活性蛋白與多肽”生物再生工程與應用科技研究，科技人員占比達37% 以上，是一家生物科技研發(fā)平臺公司。公司經(jīng)營范圍涵蓋一類新藥、醫(yī)療器械、生物高科護膚品等。
Shaanxi HuiKang Bio-Tech Co., Ltd., founded in 2001, is a biotechnology R&D platform company focusing on the biological regeneration engineering and applied science and technology research of "active proteins and peptides" in the frontier field of biotechnology. The proportion of scientific and technological personnel accounts for more than 37%. The business scope covers Class I New Drug, medical devices, biological high-tech skin care products, etc.
2010年，公司成立慧康研究院，先后投入科研經(jīng)費近億元，啟動并開展了基因工程、細胞工程領域的研究，全面進軍生物醫(yī)藥產(chǎn)業(yè)。2019年投入使用的慧康生物科技產(chǎn)業(yè)園，作為全新的研發(fā)生產(chǎn)基地，占地40畝，總建筑面積6.5萬平方米。
In 2010, the company established HuiKang Research Institute, successively invested nearly CNY100 million in scientific research, started and carried out research in the fields of genetic engineering and cell engineering, and comprehensively entered the biomedical industry. Huikang Biotechnology Industrial Park, which was put into use in 2019, as a new R & D and production base, covers an area of 40 Mu and a total construction area of 65,000 square meters.
目前，陜西慧康生物擁有一支專業(yè)的研發(fā)團隊，包括行業(yè)精英、知名大學教授等在內(nèi)70余名專家骨干。團隊長期與澳大利亞、韓國等海外生物學專家學者保持交流與合作?；劭瞪镅邪l(fā)中心是西北大學生命科學教學實習基地，并與其聯(lián)合設立研發(fā)中心；同時作為陜西科技大學食品與生物工程學院產(chǎn)學研合作基地，于2017年掛牌成為西安市博士后創(chuàng)新基地、西安市人才工作創(chuàng)新試驗基地、西安市活性蛋白與多肽工程技術研究中心。
At present, HuiKang Bio-Tech has a professional scientific research team with more than 70 experts, including industry elites and distinguished university professors. The team has maintained long-term exchanges and cooperation with oversea biological experts and scholars from Australia and Korea.HuiKang Bio-Tech R&D Center is the life science Teaching Practice Base of Northwest University, and jointly established R & D center with it; At the same time, The R&D center is also the Practice Base of Northwest University and Shaanxi University of Science and Technology. In 2017, the honors of Xi'an Post-doctoral Innovation Base, Xi'an Talent Work Innovation Experimental Base, and Xi'an Active Protein and Peptides Engineering Center were successively granted to R&D center.
截止2024年10月，慧康集團共有166項專利，包括國家發(fā)明專利88項、外觀專利18項、實用新型專利29項，中國香港專利17項， 國際專利14項?，F(xiàn)有國家I類新藥1項，醫(yī)療器械2項，西安市博士后創(chuàng)新基地項目3項，重點科研項目13項?！舵V合金-重組人源膠原復合膜的制備與測試》獲教育部國家重點實驗室項目資助，《先導多肽篩選中試共享服務平臺》以及《重組人溶菌酶滴眼液》被評為陜西省科技廳重點研發(fā)項目，《六勝肽產(chǎn)業(yè)化項目》被評為西安市科技進步獎。六勝肽科研成果論文刊登在美國《I&EC Research》雜志的封面，重組人源膠原蛋白以及膠原海綿研究成果刊登在《International Journal of Biological Macromolecules》雜志。
By the end of August 2024, Huikang group had 164 patents, including 86 national invention patents, 18 appearance patents, 29 utility model patents, 17 Hong Kong patents and 14 international patents; At present, there are 1 national class I new drug, 2 medical devices, 3 Xi'an Post Doctoral innovation base projects and 13 key scientific research projects. The preparation and testing of magnesium alloy recombinant human collagen composite membrane was supported by the National Key Laboratory Project of the Ministry of education. The pilot peptide screening pilot test sharing service platform and recombinant human lysozyme eye drops were rated as key R & D projects of Shaanxi Provincial Science and technology department. The Liusheng peptide industrialization project was rated as Xi'an Science and technology progress award. The research results of Liusheng peptide were published on the cover of i&ec research, and the research results of recombinant human collagen and collagen sponge were published in the International Journal of biological macrocells.??????????